Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: " HIV vaccine: it may take two to tango, but no party time yet"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Retrovirology cung cấp cho các bạn kiến thức về ngành y đề tài: HIV vaccine: it may take two to tango, but no party time yet. | Retrovirology BioMed Central Open Access Editorial HIV vaccine it may take two to tango but no party time yet Ben Berkhout and William A Paxton Address Laboratory of Experimental Virology Department of Medical Microbiology Center for Infectious Diseases and Immunology Amsterdam CINIMA Academic Medical Center AMC University of Amsterdam the Netherlands Email Ben Berkhout - b.berkhout@amc.uva.nl William A Paxton - w.a.paxton@amc.uva.nl Corresponding author Published 9 October 2009 Received 4 October 2009 Retrovirology 2009 6 88 doi 10.1186 1742-4690-6-88 Accepted 9 October 2009 This article is available from http www.retrovirology.com content 6 1 88 2009 Berkhout and Paxton licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract A press conference on Thursday September 24 in Bangkok Thailand released data that an experimental vaccine provided mild protection against HIV-1 infection. This is the first positive signal of any degree of vaccine efficacy in humans more than a quarter-century after scientists discovered the virus that causes AIDS. The research was conducted by a team including Thai researchers the U.S. Army and the U.S. National Institutes of Health. The RV144 Phase III clinical trial which began in 2003 had been disparaged by many critics as a waste of time and money because each of the two components had been shown to produce no benefit as individual vaccines and because the scientific rationales behind the immunogens were just wrong. It was nevertheless speculated that using them together in the prime-boost scenario could be more effective with the aim to induce heightened CD4 cellular immune responses against the viral Envelope protein. This optimism seems to have been validated. In fact this would not be the